Document Type

Article

Publication Date

3-2025

Identifier

DOI: 10.1016/j.ekir.2024.11.032; PMCID: PMC11993215

Abstract

Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) is a recognized complication of kidney failure, which can lead to short stature, bone deformity, slipped capital femoral epiphysis, and bone fracture in children. Despite the use of conventional therapies, a subgroup of patients receiving dialysis continues to experience secondary or even tertiary hyperparathyroidism. Cinacalcet, a calcimimetic agent, has been shown to be a promising therapeutic option to control hyperparathyroidism with reasonable safety profiles in adults and older children. Nevertheless, there is a paucity of data and guidance pertaining to its use among the younger children on dialysis, who are often the most challenging patients to manage with severe CKD-MBD. In this review, we summarize the available evidence on cinacalcet use among pediatric patients, especially infants and young children aged < 3 years. We also discuss the unique considerations in management and attempt to provide a pragmatic approach regarding the use of cinacalcet in this specific patient population.

Journal Title

Kidney Int Rep

Volume

10

Issue

3

First Page

696

Last Page

706

PubMed ID

40225398

Keywords

CKD-MBD; ESKD; children; cinacalcet; dialysis; pediatric nephrology

Comments

This article is available under the Creative Commons CC-BY-NC-ND license and permits non-commercial use of the work as published, without adaptation or alteration provided the work is fully attributed.

Publisher's Link: https://www.kireports.org/article/S2468-0249(24)02054-0/fulltext

Download

Share

COinS